Atrium TherapeuticsRNA +2.61%12 Return-on-Tangible-Asset is -23.32% as of Mar. 2026. GuruFocus rates RNA with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 1,417 Biotechnology companies, Atrium Therapeutics ranks better than 60.76% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Atrium Therapeutics's annualizedNet Income for the quarter that ended in Mar. 2026 was $-66.53 Mil. Atrium Therapeutics's average total tangible assets for the quarter that ended in Mar. 2026 was $285.36 Mil. Therefore, Atrium Therapeutics's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was -23.32%.
The historical rank and industry rank for Atrium Therapeutics's Return-on-Tangible-Asset or its related term are showing as below:
RNA'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -287.45 Med: -62.03 Max: -22.88
Current: -22.88
During the past 3 years, Atrium Therapeutics's highest Return-on-Tangible-Asset was -22.88%. The lowest was -287.45%. And the median was -62.03%.
RNA's Return-on-Tangible-Asset is ranked better than 60.76% of 1417
companies
in the Biotechnology industry
Industry Median: -35.77
vs RNA: -22.88
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Atrium Therapeutics Return-on-Tangible-Asset Related Terms
Atrium Therapeutics Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Atrium Therapeutics's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RNA vs CNTN, QTTB, TARA: Return-on-Tangible-Asset Comparison
For the Biotechnology subindustry, Atrium Therapeutics's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Atrium Therapeutics Return-on-Tangible-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Atrium Therapeutics's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Atrium Therapeutics's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of -23.32% mean?
Atrium Therapeutics (RNA) has a Return-on-Tangible-Asset of -23.32% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Atrium Therapeutics and its competitors. According to the industry distribution chart, Atrium Therapeutics ranks #556 out of 1417 companies in the Biotechnology industry, placing it in the top 39.2%.
Is Atrium Therapeutics' Return-on-Tangible-Asset too high?
Atrium Therapeutics' current Return-on-Tangible-Asset is -23.32%. Based on the distribution chart, Atrium Therapeutics ranks #556 out of 1417 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Atrium Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Atrium Therapeutics' Return-on-Tangible-Asset compare to CNTN and QTTB?
According to the Biotechnology industry distribution chart, Atrium Therapeutics ranks #556 out of 1417 companies for Return-on-Tangible-Asset. This puts Atrium Therapeutics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Biotechnology company?
A good Return-on-Tangible-Asset depends on the Biotechnology industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Atrium Therapeutics and its competitors. Atrium Therapeutics's current Return-on-Tangible-Asset is -23.32%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atrium Therapeutics stock overvalued right now?
Atrium Therapeutics (RNA) has a current Return-on-Tangible-Asset of -23.32%. The current Return-on-Tangible-Asset is -23.32%. Atrium Therapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Atrium Therapeutics (RNA), the current Return-on-Tangible-Asset is -23.32% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Address10578 Science Center Drive, Suite 125, San Diego, CA, USA, 92121
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.
12GF Score
Get the complete analysis for RNA
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RNA has been successfully added to your 